Organogenesis Holdings Inc. DEF 14A: Executive Compensation Details
Ticker: ORGO · Form: DEF 14A · Filed: May 12, 2025 · CIK: 1661181
| Field | Detail |
|---|---|
| Company | Organogenesis Holdings INC. (ORGO) |
| Form Type | DEF 14A |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, shareholder-meeting, corporate-governance
TL;DR
Organogenesis Holdings Inc. DEF 14A out: Executive pay details for 2024, focusing on equity awards.
AI Summary
Organogenesis Holdings Inc. filed a DEF 14A on May 12, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, including equity awards granted to Named Executive Officers (NEOs) and Non-NEOs. Specific tables outline the fair value of outstanding and unvested equity awards as of year-end 2024, and changes in the fair value of awards granted in prior years.
Why It Matters
This filing provides transparency into how Organogenesis Holdings Inc. compensates its top executives, which can influence investor perception and corporate governance.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures about executive compensation and shareholder matters, but can sometimes reveal information about potential governance issues or significant changes in executive pay structures.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for compensation details)
- 20250512 — Filing Date (Date the DEF 14A was filed with the SEC)
Key Players & Entities
- Organogenesis Holdings Inc. (company) — Filer
- Avista Healthcare Public Acquisition Corp. (company) — Former company name
- 0001661181 (company) — Central Index Key
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide detailed information regarding the company's executive compensation, director compensation, and other corporate governance matters, as required by the SEC.
What specific compensation elements are detailed for Named Executive Officers (NEOs) in this filing?
The filing details equity awards, including their fair value at grant, outstanding and unvested awards at year-end, and changes in fair value of prior year awards for NEOs.
When was Organogenesis Holdings Inc. formerly known as?
Organogenesis Holdings Inc. was formerly known as Avista Healthcare Public Acquisition Corp., with a name change effective December 15, 2015.
What is the fiscal year end for Organogenesis Holdings Inc.?
The fiscal year end for Organogenesis Holdings Inc. is December 31.
What is the SIC code for Organogenesis Holdings Inc.?
The Standard Industrial Classification (SIC) code for Organogenesis Holdings Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 12, 2025 regarding Organogenesis Holdings Inc. (ORGO).